![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Akidil, Ezgi 
ORCID: https://orcid.org/0000-0001-6873-1916; Albanese, Manuel ORCID: https://orcid.org/0000-0002-4614-7599; Buschle, Alexander ORCID: https://orcid.org/0000-0001-6126-514X; Ruhle, Adrian ORCID: https://orcid.org/0000-0002-8132-9814; Pich, Dagmar; Keppler, Oliver T. ORCID: https://orcid.org/0000-0002-1384-8946 und Hammerschmidt, Wolfgang ORCID: https://orcid.org/0000-0002-4659-0427
(2021):
Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection.
In: PLOS Pathogens 17(4), e1009117 [PDF, 1MB]
ORCID: https://orcid.org/0000-0001-6873-1916; Albanese, Manuel ORCID: https://orcid.org/0000-0002-4614-7599; Buschle, Alexander ORCID: https://orcid.org/0000-0001-6126-514X; Ruhle, Adrian ORCID: https://orcid.org/0000-0002-8132-9814; Pich, Dagmar; Keppler, Oliver T. ORCID: https://orcid.org/0000-0002-1384-8946 und Hammerschmidt, Wolfgang ORCID: https://orcid.org/0000-0002-4659-0427
(2021):
Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection.
In: PLOS Pathogens 17(4), e1009117 [PDF, 1MB]
Buschle, Alexander; Mrozek-Gorska, Paulina; Cernilogar, Filippo M.; Ettinger, Andreas; Pich, Dagmar; Krebs, Stefan; Mocanu, Bianca; Blum, Helmut; Schotta, Gunnar; Straub, Tobias und Hammerschmidt, Wolfgang
(2021):
Epstein-Barr virus inactivates the transcriptome and disrupts the chromatin architecture of its host cell in the first phase of lytic reactivation.
In: Nucleic Acids Research, Bd. 49, Nr. 6: S. 3217-3241
Liu, Wen-Hsin; Mrozek-Gorska, Paulina; Wirth, Anna-Katharina; Herold, Tobias; Schwarzkopf, Larissa; Pich, Dagmar; Voelse, Kerstin; Melo-Narvaez, M. Camila; Carlet, Michela; Hammerschmidt, Wolfgang und Jeremias, Irmela
(2020):
Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL.
In: Biomarker Research, Bd. 8, Nr. 1, 46